![Marcos Quintela-Vazquez AFHEA](https://profiles-cardiff.imgix.net/attachments/6794?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Marcos Quintela-Vazquez
AFHEA
Cydymaith Ymchwil Ôl-ddoethurol
- Ar gael fel goruchwyliwr ôl-raddedig
Ysgol y Biowyddorau
Trosolwyg
Rwy'n ymchwilydd ôl-ddoethurol yn Sefydliad Ymchwil Bôn-gelloedd Canser Ewrop (ECSCRI), sydd ar hyn o bryd yn gweithio gyda Dr Helen Pearson mewn prosiect Prostate Cancer UK sy'n ymchwilio i driniaeth newydd yn erbyn canser y prostad.
Mae fy mhrif ddiddordebau ymchwil yn canolbwyntio ar ddeall rhwydweithiau rheoleiddio sy'n gysylltiedig â chanser i nodi strategaethau therapiwtig manwl gywir a diagnosteg cydymaith. Yn ystod fy ngyrfa, rwyf wedi ymgysylltu â meysydd ymchwil sy'n amrywio o ganser yr ofari / endometrial/prostad, epigeneteg, biowybodeg a darganfod / datblygu cyffuriau.
Cyhoeddiad
2024
- Vaiasicca, S. et al. 2024. Transcriptomic analysis reveals the anti-cancer effect of gestational mesenchymal stem cell secretome. Stem Cells Translational Medicine 13(7), pp. 693-710. (10.1093/stcltm/szae024)
- James, D. W. et al. 2024. Homeobox regulator Wilms Tumour 1 is displaced by androgen receptor at cis-regulatory elements in the endometrium of PCOS patients. Frontiers in Endocrinology 15, article number: 1368494. (10.3389/fendo.2024.1368494)
- Turnham, D. J. et al. 2024. Development and characterisation of a new patient-derived Xenograft model of AR-negative metastatic asctration-resistant prostate cancer. Cells 13(8), article number: 673. (10.3390/cells13080673)
2023
- Vaiasicca, S. et al. 2023. Transcriptomic analysis of stem cells from chorionic villi uncovers the impact of chromosomes 2, 6 and 22 in the clinical manifestations of Down syndrome. Stem Cell Research and Therapy 14(1), article number: 265. (10.1186/s13287-023-03503-4)
- Quintela, M. et al. 2023. In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer. British Journal of Cancer 129(1), pp. 163–174. (10.1038/s41416-023-02274-2)
- Toubhans, B. et al. 2023. Selenium nanoparticles modulate histone methylation via lysine methyltransferase activity and S-adenosylhomocysteine depletion. Redox Biology 61, article number: 102641. (10.1016/j.redox.2023.102641)
- Quintela, M. et al. 2023. Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells. Clinical Epigenetics 15(1), article number: 63. (10.1186/s13148-023-01477-x)
2022
- Finall, A., James, D., Quintela-Vazquez, M. and Conlan, R. 2022. Differential expression of long non-coding Ribonucleic Acid (RNA) genes in endometriosis-associated ovarian cancer (EAOC): a pilot meta-analysis for pathological insights and potential diagnostic biomarker identification. Journal of Experimental Pathology 3(2), pp. 40-54. (10.33696/pathology.3.039)
- Paradiso, F. et al. 2022. Studying activated fibroblast phenotypes and fibrosis-linked mechanosensing using 3D biomimetic models. Macromolecular Bioscience 22(4), article number: 2100450. (10.1002/mabi.202100450)
- Bauza-Mayol, G. et al. 2022. Biomimetic scaffolds modulate the posttraumatic inflammatory response in articular cartilage contributing to enhanced neoformation of cartilaginous tissue in vivo. Advanced Healthcare Materials 11(1), article number: 2101127. (10.1002/adhm.202101127)
2020
- Friguglietti, J. et al. 2020. Novel silicon titanium diboride micropatterned substrates for cellular patterning. Biomaterials 244, article number: 119927. (10.1016/j.biomaterials.2020.119927)
2019
- Younas, K. et al. 2019. Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11. Journal of Molecular Medicine 97(9), pp. 1315–1327. (10.1007/s00109-019-01809-6)
- Quintela, M. et al. 2019. HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction pathways and membrane elasticity in ovarian cancer cells. Nanomedicine: Nanotechnology, Biology and Medicine 17, pp. 254-265. (10.1016/j.nano.2019.01.017)
Articles
- Vaiasicca, S. et al. 2024. Transcriptomic analysis reveals the anti-cancer effect of gestational mesenchymal stem cell secretome. Stem Cells Translational Medicine 13(7), pp. 693-710. (10.1093/stcltm/szae024)
- James, D. W. et al. 2024. Homeobox regulator Wilms Tumour 1 is displaced by androgen receptor at cis-regulatory elements in the endometrium of PCOS patients. Frontiers in Endocrinology 15, article number: 1368494. (10.3389/fendo.2024.1368494)
- Turnham, D. J. et al. 2024. Development and characterisation of a new patient-derived Xenograft model of AR-negative metastatic asctration-resistant prostate cancer. Cells 13(8), article number: 673. (10.3390/cells13080673)
- Vaiasicca, S. et al. 2023. Transcriptomic analysis of stem cells from chorionic villi uncovers the impact of chromosomes 2, 6 and 22 in the clinical manifestations of Down syndrome. Stem Cell Research and Therapy 14(1), article number: 265. (10.1186/s13287-023-03503-4)
- Quintela, M. et al. 2023. In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer. British Journal of Cancer 129(1), pp. 163–174. (10.1038/s41416-023-02274-2)
- Toubhans, B. et al. 2023. Selenium nanoparticles modulate histone methylation via lysine methyltransferase activity and S-adenosylhomocysteine depletion. Redox Biology 61, article number: 102641. (10.1016/j.redox.2023.102641)
- Quintela, M. et al. 2023. Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells. Clinical Epigenetics 15(1), article number: 63. (10.1186/s13148-023-01477-x)
- Finall, A., James, D., Quintela-Vazquez, M. and Conlan, R. 2022. Differential expression of long non-coding Ribonucleic Acid (RNA) genes in endometriosis-associated ovarian cancer (EAOC): a pilot meta-analysis for pathological insights and potential diagnostic biomarker identification. Journal of Experimental Pathology 3(2), pp. 40-54. (10.33696/pathology.3.039)
- Paradiso, F. et al. 2022. Studying activated fibroblast phenotypes and fibrosis-linked mechanosensing using 3D biomimetic models. Macromolecular Bioscience 22(4), article number: 2100450. (10.1002/mabi.202100450)
- Bauza-Mayol, G. et al. 2022. Biomimetic scaffolds modulate the posttraumatic inflammatory response in articular cartilage contributing to enhanced neoformation of cartilaginous tissue in vivo. Advanced Healthcare Materials 11(1), article number: 2101127. (10.1002/adhm.202101127)
- Friguglietti, J. et al. 2020. Novel silicon titanium diboride micropatterned substrates for cellular patterning. Biomaterials 244, article number: 119927. (10.1016/j.biomaterials.2020.119927)
- Younas, K. et al. 2019. Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11. Journal of Molecular Medicine 97(9), pp. 1315–1327. (10.1007/s00109-019-01809-6)
- Quintela, M. et al. 2019. HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction pathways and membrane elasticity in ovarian cancer cells. Nanomedicine: Nanotechnology, Biology and Medicine 17, pp. 254-265. (10.1016/j.nano.2019.01.017)
Addysgu
Darlithydd Gwadd (Prifysgol Abertawe)
- MSc. Technegau mesur labordy ar gyfer cemeg meddyginiaethol a nanofeddygaeth:
- Dilyniannu'r genhedlaeth nesaf (1h, 2022-2023).
- PCR / qRT-PCR (1h, 2019-2023).
- ELISA, blot gorllewinol ac electrofforesis (1h, 2019-2023).
- MSc. Nanofeddygaeth, Fferyllol a Therapeutics Uwch:
- Targedau, camau gweithredu a derbynyddion (2h, 2019-parhaus).
- BSc. Epigeneteg, rheoleiddio genynnau a chlefydau:
- Mae Histone yn addasu I / II (2h, 2021-2023).
- Rheoliad Gene (1h, 2023).
- Ffactorau trawsgrifio (1h, 2023).
Bywgraffiad
- Cydymaith Ymchwil ym Mhrifysgol Caerdydd (cyfredol).
- Prosiect Prostate Cancer UK dan arweiniad Dr Helen Pearson.
- Ymchwilio i BCL3 fel targed therapiwtig i drin canser y prostad.
- Cydymaith Ymchwil ym Mhrifysgol Abertawe (2019-2023).
- Cydweithrediad diwydiannol gyda Continuum Life Sciences Ltd dan arweiniad yr Athro Steven Conlan.
- Prosiect 'Clwstwr ar gyfer Cyffuriau Epigenomig a Gwrthgyrff sy'n Cymysgu Therapeutics' a ariennir gan Gronfa Datblygu Rhanbarthol Ewrop drwy Lywodraeth Cymru. Cydweithrediad diwydiannol gyda GlaxoSmithKline a Porvair Sciences Ltd dan arweiniad yr Athro Lewis W Francis a'r Athro Deyarina Gonzalez.
- Swyddog Ymchwil Data ym Mhrifysgol Abertawe (2017-2018).
- PhD mewn Nanofeddygaeth (2018)
- Prosiect ar y cyd rhwng Prifysgol Abertawe a Sefydliad Ymchwil Methodistaidd Houston (2 flynedd).
- Effaith HBO1 mewn canser yr ofari Prosiect dan arweiniad yr Athro Steven Conlan a Dr Paul Webb.
- MSc mewn Biotechnoleg Moleciwlaidd a Therapiwtig ym Mhrifysgol Ymreolaethol Barcelona (1af, 2013).
- BSc mewn Biotechnoleg ym Mhrifysgol Salamanca (2:1, 2012).
Ymrwymiadau siarad cyhoeddus
- Siaradwr gwadd ym Mhrifysgol A Coruña yn y 'Ganolfan Ryngddisgyblaethol ar gyfer Cemeg a Bioleg (CICA)' a safle 'Hospital Materno' (2023).
- Cyflwyniad yn 'Seminar Ymarfer Effeithiol Academi Dysgu ac Addysgu Abertawe (SALT): Ymchwilwyr sy'n addysgu, gan ennill cydnabyddiaeth fel ymchwilydd ôl-ddoethurol'. (2023).
- Cyfweliad ar-lein ar gyfer porth Newyddion Gwyddorau Bywyd Meddygol: Hyrwyddo Diagnosis a Thriniaeth Canser yr Ofari (2021). Cyswllt: https://www.news-medical.net/news/20210407/Advancing-the-Diagnosis-and-Treatment-of-Ovarian-Cancer.aspx
Pwyllgorau ac adolygu
- Adolygydd gwirfoddol ar gyfer cyfnodolion Elsevier.
- 2 adolygiadau wedi'u cwblhau yn Redox Biology.
- 2 adolygiadau wedi'u cwblhau mewn adroddiadau canser.
- Cynrychiolydd Gyrfa Gynnar ar Bwyllgor Maes Ymchwil V (Signalau) y Gymdeithas Biocemegol.
- Aelod o'r pwyllgor gwyddonol yn Symposiwm Heneiddio Cellog a Metabolaeth 2024 (Gorffennaf 2024, A Coruña).
- Aelod o Bwyllgor Canser Cymdeithas Ymchwilwyr Sbaen yn y Deyrnas Unedig (CERU).
- Aelod o'r Ymchwilwyr Gyrfa Gynnar yn Commitee ym Mhrifysgol Caerdydd
Meysydd goruchwyliaeth
Prosiectau'r gorffennol
Prifysgol Caerdydd:
- MSc. Ymchwilio i'r echelin NFkb-BCL3 mewn celloedd canser y prostad sy'n gwrthsefyll castration (Mehefin-Medi 2024).
Prifysgol Abertawe:
- MSc. Ymchwilio i fecanwaith gweithredu hibiors PLK1 a BRD4 yn HGSOC (Medi 2022-Gorffennaf 2023).
- BSc. trin fferyllol y llwybr rheoleiddio SUV39H2-LSD1 mewn canser yr ofari (Ionawr-Mai 2023).
- Bsc. Effaith atalydd SUV39H2 ar reoleiddio a mynegiant CYP1A1 a KRT7 (Ionawr-Mai 2023).
- BSc. Trin fferyllol y llwybr demethylase 1 lysin-benodol gan ddefnyddio atalyddion demethylase 1 lysin-benodol mewn canser yr ofari (Jan-Mai 2023).
- BSc. Ymchwilio i effeithiau i-BET726 ar carcinomas ofarïaidd ymwrthedd cisplatin (Ionawr-Mai 2022).
- BSc. Ymchwilio i effeithiau i-BET151 ar garcinomas ofarïaidd chemoresistant (Ionawr-Mai 2022).
- MSc. Mynegiant gwahaniaethol o foleciwlau RNA hir nad ydynt yn codio mewn canser ofarïaidd sy'n gysylltiedig ag endometriosis (Medi 2019 - Mai 2021).
- BSc. Adnabod mecanweithiau gwrthsefyll a strategaethau ail-sensiteiddio posibl mewn spheroidau canser yr ofari (Ionawr-Mai 2021).
- BSc. Ymchwilio i rôl epigenetig BRD4 wrth reoleiddio mynegiant NRG1 / HER3 mewn canser yr ofari (Ionawr-Mai 2020).
- MSc. Dadansoddiad biowybodol o rôl methylation JMJD3/UTX a H3K27 mewn canser yr ofari (Medi 2019-Mai 2020).
- MSc. Mae mecanweithiau epigenetig yn gyrru datblygiad therapiwtig posibl mewn canserau gynaecolegol (Ionawr 2019-Medi 2020).
Contact Details
Quintela-VazquezM@caerdydd.ac.uk
Adeilad Hadyn Ellis, Ystafell 1.19, Heol Maendy, Caerdydd, CF24 4HQ
Adeilad Hadyn Ellis, Ystafell 1.19, Heol Maendy, Caerdydd, CF24 4HQ
Themâu ymchwil
Arbenigeddau
- Bioleg celloedd canser
- Biowybodeg
- Genomeg a thrawsgrifiadau
- Darganfod Cyffuriau Trosiadol
- Therapi canser